Spero Therapeutics Inc (NAS:SPRO)
$ 1.03 0.0861 (9.12%) Market Cap: 56.15 Mil Enterprise Value: -20.21 Mil PE Ratio: 12.88 PB Ratio: 0.85 GF Score: 39/100

Spero Therapeutics Inc KOL Breakfast Symposium: A Focus on the Spero Pipeline Transcript

Dec 05, 2019 / 01:30PM GMT
Release Date Price: $11.43 (+0.53%)
Sharon Klahre
Spero Therapeutics, Inc. - Senior Director of IR

Great. Thank you, everyone, for coming to our event. We'll first dive into our Phase III product candidate, SPR994, now called tebipenem HBr, including a presentation from Dr. Yoav Golan on the unmet need in the complicated urinary tract infection area. We'll then move to SPR720. We announced the Phase I data on the compound yesterday, and our plan is to move forward into a Phase II in NTM patients. We'll be taking questions after each presentation, and I'll now pass it over to Ankit Mahadevia, President and CEO of Spero Therapeutics.

Ankit Mahadevia
Spero Therapeutics, Inc. - Co-Founder, CEO, President & Director

Thank you, Sharon, and thanks for all of you for coming in this morning and for all of you that are listening on the web. We are excited to present our progress both on 994 as well as on SPR720.

So as always, I'd like to start our discussion about our pipeline with a discussion about patients. And this is a patient named Tim, who was kind enough to share his story with the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot